Notably, pirfenidone, the first-line medication for IPF [45], has been demonstrated to suppress TGF-β signaling and was proven to have antitumor effects in pancreatic cancer [46] and lung metastasis in triple-negative breast cancer [47]. The gene discussed is TGFB1; the disease is triple-negative breast carcinoma.